by John Conrad | Dec 3, 2024 | Member News
COUR Pharmaceuticals has secured a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize its tolerogenic nanoparticle treatments for autoimmune conditions. The partnership, announced via press release...
